2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.13 Radioactive Seed Implantation Combined with PD-L1 Antibody and Chemotherapy Gt in the First-Line Treatment of ES-SCLC: A Retrospective Study.

EP.13B.13 Radioactive Seed Implantation Combined with PD-L1 Antibody and Chemotherapy Gt in the First-Line Treatment of ES-SCLC: A Retrospective Study.

Back to course

Pdf Summary

Dr. Xiaoping Li’s study explores a new approach to treating extensive-stage small-cell lung cancer (ES-SCLC) by combining radioactive seed implantation (RSI) with PD-L1 antibodies and chemotherapy as a first-line treatment. The study acknowledges the current use of immune checkpoint inhibitors alongside platinum-based chemotherapy as a standard treatment for ES-SCLC but notes the need for improved efficacy.<br /><br />RSI, known for its low doses, minimal adverse reactions, and limited invasiveness, was combined with PD-L1 antibodies, etoposide, and either cisplatin or carboplatin, administered every three weeks for four cycles. The retrospective study analyzed data from 21 patients treated from July 2020 to March 2024, comprising 15 males and 6 females with a median age of 64 years. A significant portion of the cohort had a history of smoking, with some experiencing mediastinal or bone metastasis.<br /><br />The results indicated that the treatment approach could be effective and safe. The median progression-free survival (PFS) was 10 months, while the median overall survival (OS) was 14 months. Adverse events were generally manageable, with 14% of patients experiencing grade 3/4 adverse effects.<br /><br />The study concludes that while radioactive seed implantation, combined with PD-L1 antibodies and chemotherapy, shows promise in treating ES-SCLC, larger randomized controlled trials are essential for confirming its effectiveness. This combined treatment approach potentially offers a safe and effective new option for patients with ES-SCLC, leveraging the advantages of RSI and the immunotherapeutic benefits of PD-L1 antibodies. Further investigation is needed to better understand the therapy's long-term outcomes and safety profile.

Asset Subtitle

Xiaoping Li

Meta Tag

Speaker Xiaoping Li

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

extensive-stage small-cell lung cancer

radioactive seed implantation

PD-L1 antibodies

chemotherapy

immune checkpoint inhibitors

platinum-based chemotherapy

progression-free survival

overall survival

adverse events

randomized controlled trials